Search Results
10
Everything
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
February 25, 2025 08:00 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that on December...
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
February 24, 2025 08:00 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has...
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
January 27, 2025 08:00 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Celularity issues the following announcement on behalf of the members of the MASS Coalition: MASS Coalition Welcomes Trump Order Freezing Skin...
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
December 10, 2024 08:00 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it has...
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
December 06, 2024 08:00 ET
|
Celularity Inc.
Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and...
Celularity Inc. Announces Receipt of Nasdaq Notification
November 27, 2024 17:00 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell...
Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
November 20, 2024 08:30 ET
|
Celularity Inc.
Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific regionGenting Berhad announced...
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
November 18, 2024 08:30 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing...
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
November 07, 2024 08:00 ET
|
Celularity Inc.
Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to...
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
October 23, 2024 08:30 ET
|
Celularity Inc.
FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it has requested a hearing...